spacer
home > ebr > spring 2007 > novel therapeutics from a toxin
PUBLICATIONS
European Biopharmaceutical Review

Novel Therapeutics from a Toxin

John A Chaddock and Keith Foster at Syntaxin Ltd break down the therapeutic benefits of botulinum neurotoxins

Botulinum neurotoxins (BoNTs), the causative agents of botulism, are the most potent acute lethal toxins known, with lethal doses of 10-9g/kg of body weight (1). Perhaps surprisingly, therefore, BoNTs are also a first-line Regulatory Authority approved therapy for a variety of debilitating conditions, have been reported to be effective in the treatment of over 100 conditions, and have a worldwide market value of well over US$1 billion.

BOTULINUM NEUROTOXINS AS THERAPEUTICS

Research to investigate the therapeutic potential of BoNTs was initiated in the early 1970s by Alan Scott, whose goal was to identify a drug that would benefit the correction of strabismus (squint) and to be used as an alternative to the approach of the time, which was surgery. Having injected a number of drugs into the extraocular muscles, BoNT was identified as the preferred candidate for further investigation. Its paralytic effect lasted for several weeks, with a lack of systemic side effects as well as a controllable dosage/response relationship. Scott and colleagues developed the techniques and dosing protocols to such a degree that by the 1980s BoNT was being used in the clinic to treat strabismus (2). Following this pioneering report, BoNT/A was used throughout the 1980s to treat a range of dystonias (involuntary muscle spasms), including blepharospasm (closure of the eyelids), and was shown to be a safe and effective therapy for a large number of neurological diseases.

FDA approval of BoNT/A as an orphan drug for the treatment of strabismus, blepharospasm and hemifacial spasm was given in December 1989. The drug has subsequently been approved for the treatment of cervical dystonia, glabellar wrinkles and hyperhydrosis (excessive sweating) and has been used off-label and reported to be effective in more than 100 different clinical conditions (3). In addition to their effects on muscle contraction and autonomic conditions, BoNT preparations, particularly BoNT/A, have recently been reported to relieve pain. In this, as in other indications, the toxins’ prolonged duration of action is a major advantage.

RISING SALES

The FDA-approved BoNT/A product is manufactured under the trade name BOTOX® by Allergan Inc. An alternative BoNT/A preparation, DYSPORTTM, which is not currently FDA approved but is used extensively in Europe, is manufactured by Ipsen Ltd. Although BOTOX® and DYSPORTTM are both formulations of BoNT/A, they are not interchangeable products. A preparation of BoNT/B has more recently received regulatory approval for use in cervical dystonia. This product is available from Solstice Neurosciences Inc as MYOBLOC® in the US, and NEUROBLOCTM in Europe.

THE BIOLOGY OF BONTS

There are seven immunologically distinct serotypes of botulinum neurotoxin, named BoNT/A to BoNT/G. All BoNTs exert their effect at the neuromuscular junction where they inhibit secretion of the neurotransmitter, acetylcholine, causing a flaccid paralysis. The neurotoxins have their effect by proteolytically cleaving members of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein family. These SNARE proteins are essential for the fusion of synaptic vesicles to the presynaptic membrane, and secretion of the vesicles’ contents, so their cleavage prevents neurosecretion.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer

Keith Foster is one of the Founders and Chief Scientific Officer of Syntaxin Ltd, a biopharmaceutical company focused on designing and developing bacterial protein based therapeutics for the treatment of neurological, respiratory and metabolic diseases. Keith has over 20 years’ management experience in pharmaceutical R&D. He joined Syntaxin from the Health Protection Agency, where he led the research team that developed the proprietary technology for the targeted delivery of clostridial neurotoxin endopeptidase activity. Keith has an MA in Natural Sciences from the University of Cambridge and a PhD in Biochemistry from the University of London.

John A Chaddock is Head of Molecular Biology within Syntaxin Ltd. John has over 15 years’ experience in protein engineering, the last 10 of which have been focused on developing clostridial endopeptidase retargeting technology. Prior to joining Syntaxin Ltd, John was a Senior Scientist at the Health Protection Agency. John has a BSc in Molecular Biology/Biochemistry from the University of Durham and a PhD from the University of Warwick.

spacer
Keith Foster
spacer
spacer
spacer
John A Chaddock
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

Digital Transformation of the Cold Chain

Sensitech EMEA

The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement